A Phase I, Open-label, Randomized, Parallel-arm, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Subjects
Latest Information Update: 22 Nov 2022
At a glance
- Drugs Maridebart cafraglutide (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Amgen
- 16 Mar 2022 Status changed from active, no longer recruiting to completed.
- 08 Dec 2021 Planned End Date changed from 15 Feb 2022 to 11 Mar 2022.
- 08 Dec 2021 Planned primary completion date changed from 15 Feb 2022 to 11 Mar 2022.